Journal of Neural Transmission

, Volume 75, Issue 1, pp 21–29 | Cite as

Dysbalance of neuronal second messenger function in the aetiology of affective disorders: A pathophysiological concept hypothesising defects beyond first messenger receptors

  • H. Wachtel
Original Papers
Received:
Accepted:

Summary

It is suggested that affective disorders arise from the dysbalance of the two major intraneuronal signal amplification systems, the adenylate cyclase and the phospholipase C system, with depression resulting from underfunction of cyclic adenosine 3′,5′-monophosphate-mediated effector cell responses associated with an absolute or relative dominance of the inositoltriphosphate/ diacylglycerol-mediated responses and mania resulting from the converse. The usefulness of this hypothesis is discussed with respect to (a) the mechanism of action of current therapeutic agents and (b) the development of novel therapeutic approaches.

Keywords

Depression mania second messenger dysfunction adenylate cyclase phospholiphase C made of action of antidepressants and lithium 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdulla YH, Hamadah K (1970) 3′,5′ cyclic adenosine monophosphate in depression and mania. Lancet 1: 378–381PubMedGoogle Scholar
  2. Andersen PH, Klysner R, Geisler A (1984) Fluoride-stimulated adenylate cyclase activity in rat brain following chronic treatment with psychotropic drugs. Neuropharmacology 23: 445–447PubMedGoogle Scholar
  3. Berridge MJ (1984) Inositol triphosphate and diacylglycerol as second messengers. Biochem J 220: 345–360PubMedGoogle Scholar
  4. Codina J, Hildebrandt J, Sunyer T, Sekura RD, Manclark CR, Iyengar R, Birnbaumer L (1984) Mechanisms in the vectorial receptor-adenylate cyclase signal transduction. Adv Cyclic Nucleotide Protein Phosphorylation Res 17: 111–125PubMedGoogle Scholar
  5. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113: 1237–1264PubMedGoogle Scholar
  6. Dousa T, Hechter O (1970) Lithium and brain adenyle cyclase. Lancet 1: 834–835Google Scholar
  7. Ebstein RP, Oppenheim G, Ebstein BS, Amiri Z, Stessman J (1986) The cyclic AMP second messenger system in man: The effect of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog Neuropsychopharmacol Biol Psychiatry 10: 323–353PubMedGoogle Scholar
  8. Extein I, Tallman J, Smith CC, Goodwin FK (1979) Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1: 191–197PubMedGoogle Scholar
  9. Guiot-Goffioul F, Gerard-Vanderhove MA, Troisfontaines B, Breulet M, von Frenckell R, Bobon D (1987) Preliminary results of a double-blind study between rolipram and desimipramine in hospitalized patients with major depressive symptoms. Acta Psychiatr Belg 87: 230–235PubMedGoogle Scholar
  10. Hallcher LM, Sherman WR (1980) The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 225: 10896–10901Google Scholar
  11. Horowski R, Sastre-y-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 38: 23–29Google Scholar
  12. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2: 632–635PubMedGoogle Scholar
  13. Janowsky DS, Risch SC (1984) Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. Drug Develop Res 4: 125–142Google Scholar
  14. Kaspar S, Moises HW, Beckmann H (1981) The anticholinergic biperiden in depressive disorders. Pharmacopsychiatry 14: 195–198Google Scholar
  15. Khan MC, Wickham EA, Reed JV (1987) Lithium versus placebo in acute depression: á clinical trial. Int Clin Psychopharmacol 2: 47–54PubMedGoogle Scholar
  16. Krebs EG, Beavo JA (1979) Phosphorylation-dephosphorylation of enzymes. Ann Rev Biochem 48: 923–959PubMedGoogle Scholar
  17. Levin RM, Weiss B (1976) Mechanism by which psychotropic drugs inhibit adenosine cyclic 3′,5′-monophosphate phosphodiesterase of brain. Mol Pharmacol 12: 581–589PubMedGoogle Scholar
  18. Matthysse S (1986) Animal models in psychiatric research. Prog Brain Res 65: 259–270PubMedGoogle Scholar
  19. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW (1983) Guanosine triphosphate activation of brain adenylate cyclase: Enhancement by long-term antidepressant treatment. Science 219: 65–67PubMedGoogle Scholar
  20. Mork A, Geisler A (1987) Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol 60: 241–248PubMedGoogle Scholar
  21. Namura S, Zorn SH, Enna SJ (1987) Selective interaction of tricyclic antidepressants with a subclass of rat brain cholinergic muscarinic receptors. Life Sci 40: 1751–1760PubMedGoogle Scholar
  22. Newman ME, Klein E, Birmaher B, Feinsod M, Belmaker RH (1983) Lithium at therapeutic concentrations inhibits human brain noradrenaline-sensitive cyclic AMP accumulation. Brain Res 278: 380–381PubMedGoogle Scholar
  23. Newman ME, Belmaker RH (1987) Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 26: 211–217PubMedGoogle Scholar
  24. Newman ME, Lipot M, Lerer B (1987) Differential effects of chronic administration of desipramine on the cyclic AMP response in cortical slices and membranes in the rat. Neuropharmacology 26: 1127–1130PubMedGoogle Scholar
  25. Nishizuka Y (1984) The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 308: 693–698PubMedGoogle Scholar
  26. Ohno S, Kawasaki H, Imajoh S, Suzuki K (1987) Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature 325: 161–166PubMedGoogle Scholar
  27. Ossofsky HJ (1976) Affective and atopic disorder and cyclic AMP. Compr Psychiatry 17: 335–346PubMedGoogle Scholar
  28. Pandey G, Dysken MW, Garver DL (1979) Beta-adrenergic receptor function in affective illness. Am J Psychiatry 136: 675–678PubMedGoogle Scholar
  29. Przegalinski E, Bigajska K (1983) Antidepressant properties of some phosphodiesterase inhibitors. Pol J Pharmacol Pharm 35: 233–240PubMedGoogle Scholar
  30. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122: 509–522PubMedGoogle Scholar
  31. Snyder SH, Yamamura HI (1977) Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34: 236–239PubMedGoogle Scholar
  32. Stone EA (1983) Problems with current catecholamine hypotheses of antidepressant agents: Speculations leading to a new hypothesis. Behav Brain Sci 6: 535–577Google Scholar
  33. Strada SJ, Martin MW, Thompson WJ (1984) General properties of multiple molecular forms of cyclic nucleotide phosphodiesterase in the nervous system. Adv Cyclic Nucleotide Protein Phosphorylation Res 16: 13–29PubMedGoogle Scholar
  34. Sulser F (1983) Deamplification of noradrenergic signal transfer by antidepressants: a unified catecholamine-serotonin hypothesis of affective disorders. Psychopharmacol Bull 19: 300–304PubMedGoogle Scholar
  35. Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257: 495–496PubMedGoogle Scholar
  36. Wachtel H (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22: 367–372PubMedGoogle Scholar
  37. Wachtel H, Löschmann PA (1986) Effects of forskolin and cyclic nucleotides in animal model predictive of antidepressant activity: Interactions with rolipram. Psychopharmacology 90: 430–435PubMedGoogle Scholar
  38. Willner P (1984) The ability of antidepressant drug to desensitize β-receptors is inversely correlated with their clinical potency. J Affective Disord 7: 53–58Google Scholar
  39. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M (1984) Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17: 188–120PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • H. Wachtel
    • 1
  1. 1.Research Laboratories of Schering AGBerlin and BergkamenGermany

Personalised recommendations